KIT and melanoma: Confirming the screen results, varying concentrations of ganetespib increased the sensitivity of 2549 and 2338, and additional human melanoma cell lines 2400 and 2559 (BRAF V600E mutated), 2812 (wild type for BRAF, NRAS and cKIT) to T-cell-mediated killing (Fig. 1b and Supplementary Fig. 2B).